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MortalityBackground: The Heart Failure (HF) Meta-score may be useful in predicting prognosis in patients with primary
prevention cardiac resynchronization defibrillators (CRT-D) considering the competing risk of appropriate defi-
brillator shock versus mortality.
Methods: Data from 648 consecutive patients from two centers were used for the evaluation of the performance
of the HF Meta-score. The primary endpoint was mortality and the secondary endpoint was time to first appro-
priate implantable cardioverter-defibrillator (ICD) shock or deathwithout prior appropriate ICD shock. Fine-Gray
model was used for competing risk regression analysis.
Results: In the entire cohort, 237 patients died over a median follow-up of 5.2 years. Five-year cumulative inci-
dence of mortality ranged from 12% to 53%, for quintiles 1 through 5 of the HF Meta-score, respectively (log-
rank P < 0.001). Compared with the lowest quintile, mortality risk was higher in the highest quintile (HR 6.9;
95%CI 3.7–12.8). The HF Meta-score had excellent calibration, accuracy, and good discrimination in predicting
mortality (C-statistic 0.76 at 1-year and 0.71 at 5-year). The risk of death without appropriate ICD shock was
higher in risk quintile 5 compared to quintile 1 (sub HR 5.8; 95%CI 3.1–11.0, P < 0.001).
Conclusions:Our study demonstrated a good ability of theHFMeta-score to predict survival inHF patients treated
with CRT-D as primary prevention. The HF Meta-score proved to be useful in identifying a subgroup with a sig-
nificantly poor prognosis despite a CRT-D.
© 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Heart failure (HF) is a progressive disease associated with highmor-
bidity and mortality. The prevalence of HF is increasing with high bur-
den of costs and loss of quality of life [1,2]. Data from randomized
clinical trials have shown a benefit of cardiac resynchronization therapy
(CRT) in reducing morbidity and mortality in selected patients with
drug refractory HF, reduced left ventricular ejection fraction (LVEF),
and electrical dyssynchrony [3–6]. As the majority of patients with HF
with reduced EF (HFrEF) have a potential indication for a prophylactic
implantable defibrillator (ICD), ICDs combined with CRT (CRT-D) are
part of standard management in patients with HFrEF and left bundle
branch block [7,8]. Despite the beneficial effects of CRT, mortality is
not uniform among patients as CRT-candidates have heterogeneousErasmus MC, Room Rg-632, PO
uns).
. This is an open access article under
. Schaer, K. Caliskan, et al., App
nal of Cardiology, https://doirisk profiles. Patients may have mild to severe HF, different etiology of
HF, and different burden of various potentially co-existing comorbidi-
ties. Severalmodels have been developed to predictmortality risk in pa-
tients with HF, such as the Seattle Heart Failure Model (SHFM) and the
Heart Failure Survival Score (HFSS) [9,10]. Recently, a novel prediction
model derived from ameta-analysis, the HFMeta-score, was developed
[11]. The provincial Ontario database was used for validation which in-
cluded amixed population of patients with primary and secondary pre-
vention indication treatedwith ICDs or CRT-Ds, 19% of whom received a
de novo CRT implantation. As a consequence, the performance of this
novel prediction model in primary prevention patients with a CRT-D is
unknown. The aim of this study was to assess the performance of the
HF Meta-score when applied to a real-world cohort of primary preven-
tion patientswhounderwent CRT-D implantation. In addition, the ratio-
nale to implant a CRT-D depends on two mutually exclusive competing
events, appropriate ICD shocks and death without prior ICD therapy.
Therefore, we also evaluated whether predicted risks by the HF Meta-
score could identify the subset of patients who die before appropriate
ICD shocks.the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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2.1. Study population
We used data from two prospective ICD registries of the cardiology
departments of Erasmus MC (Rotterdam, the Netherlands) and the
University Hospital of Basel (Basel, Switzerland). In these registries,
we identified all patients in whom a CRT-D was implanted for chronic
HF and primary prevention of sudden cardiac death (SCD) between Jan-
uary 2005 to December 2017 (Rotterdam cohort n = 426; Basel cohort
n=222). In both cohorts, CRT implantationwas indicated by symptom-
atic HF despite optimal medical therapy, an impaired LVEF (≤35%), and
the presence of an inter- or intraventricular conduction delay (QRS du-
ration ≥ 130 ms). The administrative censoring date was set at the end
of December 2018 for all patients alive until that date. Over the years, in-
dications for CRT and programming of devices have changed, in order to
identify possible trends, we defined three groups according to the im-
plant year (1: 2005–2009; 2: 2010–2014; 3: 2015–2017).
The study protocol was approved by the IRB of the Erasmus MC
(MEC 2018-1713) and the University Hospital of Basel (BASEC 2018-
329). This retrospective study was not subjected to the Dutch Medical
Research Involving Human Subjects Act and the need for written in-
formed consent was waived. The study was carried out according to
the ethical principles for medical research involving human subjects
established by the Declaration of Helsinki. The privacy of all patients
and the confidentiality of their personal information were protected.2.2. Data collection
This study included a total of 648 CRT-D patients. Demographic and
clinical data listed in Table 1 were obtained before implantation. La-
boratory data were collected the day before implantation. For allTable 1
Baseline characteristics of the study cohort (n = 648).
Variable
Age (y) 66 (58–72)
Male gender 492 (76%)
Atrial fibrillation 125 (19%)





LVEF (%) 25 ± 6
QRS duration (ms) 167 ± 23
Heart failure admission 1 year prior to implantation 208 (32%)
Comorbidities
Diabetes mellitus 163 (25%)
Chronic obstructive pulmonary disease 85 (13%)
Peripheral vascular disease 53 (8%)
Laboratory data
Sodium (mmol/l) 139 ± 4
Hemoglobin (g/dl) 13.6 ± 1.7
Creatinine (mg/dl) 1.1 (0.9–1.5)
Glomerular filtration rate (ml/min/1.73 m2) 64 (47–82)








Continuous data are expressed as mean ± SD or median (interquartile range), and cate-
gorical data as number (percentage).
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; LVEF,
left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NYHA,
New York Heart Association.
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patients, the renal function was assessed by estimating the glomerular
filtration rate (eGFR) using the abbreviated Modification of Diet in
Renal Disease equation [12]. Impaired renal function was defined as
an eGFR < 60 ml/min/1.73 m2 according to practice guidelines.
2.3. Follow-up and ICD therapy event analysis
Follow-up started at the time of CRT-D implantation. In Rotterdam,
patients were seen at 2 weeks; at 3, and 6 months after implantation;
and at 6-month intervals thereafter. In Basel, patients were seen at 1,
3, and 6months after implantation, and also at 6-month intervals there-
after. The programming of the ventricular tachycardia (VT) zonewas set
to 170–180 bpm. The ventricular fibrillation (VF) zone was set to
220–240 bpm. At each visit, arrhythmic events with stored electro-
grams (EGMs) were retrieved from the device's memory. Appropriate
ICD therapy was defined as ICD therapy delivered for VT/VF. The pres-
ence of atrioventricular dissociation (ventricular rate > atrial rate)
was used to diagnose ventricular tachyarrhythmia when the baseline
atrial rhythm is sinus rhythm. In case of atrial fibrillation as baseline
atrial rhythm, ventricular tachyarrhythmias were defined as events
with a sudden increase in rate combined with a change in ventricular
near-field and far-field EGM morphology from the baseline rhythm
without biventricular pacing.
2.4. Endpoints
The primary endpoint was all-cause mortality. Patients who
underwent cardiac transplantation or left ventricular assist device
(LVAD) implantation were censored at the time of surgery. The second-
ary endpoint was time from CRT-D implantation to either the occur-
rence of appropriate ICD shock within the VF zone of the device
(being ‘potentially life-threatening’) or death without prior appropriate
ICD shock (so-called ‘prior death’). In the current study, death without
prior appropriate ICD shock is the event of interest. The competing
risk event is appropriate ICD shock. In case of tied events, the more se-
rious event was always coded. If, for example, appropriate shock in
the VF zone and death were tied on the same day, it was counted as
death.
2.5. Application of the Heart Failure Meta-score
The predictive HFMeta-score is constructed of independentmortal-
ity predictors identified in a meta-analysis. These predictors include 3
continuous variables: age, LVEF and eGFR; a categoric variable: New
York Heart Association (NYHA) functional class; and 11 dichotomous
variables: male gender, African-American race, diabetes, chronic ob-
structive pulmonary disease (COPD), peripheral vascular disease
(PVD), ischemic cardiomyopathy (iCMP), HF admission within 1 year
prior to implantation, past or present atrial fibrillation, wide QRS
(≥120 ms), secondary prevention indication, and history of ICD shocks
(appropriate and inappropriate). For all patients, the HF Meta-score
was calculated using the mathematical formula as previously described
by Alba et al. [11] As we evaluated primary prevention patients with a
CRT-D in our study, the variable wide QRS (≥120 ms) was answered
‘yes’, while secondary prevention indication and history of ICD shocks
were answered ‘no’.
2.6. Statistical analysis
Descriptive statistics are presented as mean and SD for continuous
variables, if normally distributed, or as median and 25th and 75th per-
centiles. Data were compared with the Student's t-test or the Mann-
Whitney U test, where appropriate. Categorical data were expressed
as percentages and compared with Fisher's exact test. Although most
patients had a relatively complete dataset, the method of multiple
D.A.M.J. Theuns, B.A. Schaer, K. Caliskan et al. International Journal of Cardiology xxx (xxxx) xxximputation was used to include variables with <5% of missing data;
LVEF 3.5%, creatinine 0.9%, and NYHA 1.6%.
The calculated HF Meta-score was converted to event-free survival
probabilities up to 5 years for each individual patient (i.e. predicted
survival). The observed survival rates were calculated according to
the Kaplan-Meier method, and differences between risk quintiles
were evaluated by the log-rank test. Discrimination was assessed by
using the Harrell's C-statistic for time-to-event data. Model discrimi-
nation was deemed poor if the C-statistic was between 0.50 and
0.70, good between 0.70 and 0.80, and excellent if >0.80. Model cali-
bration was visualized by plotting the predicted risks against the ob-
served risks in a calibration-in-the-large plot stratifying by risk
quintiles, and further described by the calibration slope and intercept.
The intercept was used to assess whether the model predictions are
systematically too low or too high. In case of perfect calibration,
which means that the percentage predicted outcome is equal to the
observed percentage, the intercept is 0. If outcome rate is
overestimated, the intercept is negative and vice versa. The calibration
slope, which in an ideal case equals 1, reflects how close the predicted
average risk by quintiles is to the observed risk [13]. The Hosmer-
Lemeshow goodness-of-fit test was also used to assess calibration.
As a measure of accuracy, the Brier score was calculated, which is
the averaged squared difference between predicted and observed
values. The Brier score ranges from 0 to 1; lower scores being better,
a score of 0 indicates a perfect model. Usually, a model is considered
useful if the Brier score is <0.25. To explore whether the HF Meta-
score adds to ICD decision making, competing risk analysis was per-
formed. We used cumulative incidence functions (CIFs), which is the
probability of occurrence of a particular event by time t in the pres-
ence of competing events. The associated CIF plots were constructed.
To analyze the effect of the HF Meta-score, the proportional
subdistribution hazard model as proposed by Fine and Gray was
used [14]. Subhazard ratios (SHRs) are presented with corresponding
95% confidence intervals (CIs). Statistical analysis was performed
using Stata version 16 SE for Windows (StataCorp, College Station,
TX) and R statistical software, version 3.5.3. Statistical significance
was defined as P < 0.05 (two-tailed).Fig. 1. Five-year survival by risk quintile pre
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3. Results
The baseline characteristics of the study population are presented in
Table 1. Briefly, median age of the study populationwas 66 years (range
58 to 72 years) and 76%weremale. Sixty-six percent of patients were in
NYHA functional class III or IV,mean LVEFwas25±6%, and 47%percent
had ischemic cardiomyopathy.
During a median follow-up of 5.2 years (range 2.3 to 8.7 years), 237
patients died, 8 underwent cardiac transplantation, and 5 underwent
LVAD implantation. The mode of death was sudden, including arrhyth-
mic, in 10%, end-stage HF in 46%, non-cardiac in 28%, and unknown in
16%. Overall, the annual mortality rate was 5.6% (95% CI 5.5%–5.7%),
yielding amortality rate of 6%, 18%, and 37%, at 1, 3, and 5 years, respec-
tively. Mortality was not different between the different implant pe-
riods (P = 0.25). The Kaplan-Meier survival curves according to
quintiles of the HF Meta-score estimated risk are shown in Fig. 1. At 5-
years follow-up, mortality ranged from 12% (95% CI, 7%–20%) to 53%
(95% CI, 44%–62%), for quintiles 1 to 5, respectively (overall log-rank
P < 0.001). Mortality risk was increased with ascending quintiles of
HF Meta-score, with a 6.9-fold higher mortality (HR 6.9; 95% CI,
3.7–12.8) in the highest quintile compared to the lowest quintile
(Table 2).
Model discrimination assessed by C-statistic was 0.76 (95% CI,
0.71–0.82) at 1 year and 0.71 (95% CI, 0.66–0.76) at 5 years. Model cal-
ibration was excellent as assessed by the calibration plot (Fig. 2), show-
ing a calibration slope of 1 with an intercept of 0 indicating that the
predicted risks were not over- or underestimated. No evidence of lack
of fit was also assessed by the Hosmer-Lemeshow test (chi-square =
3.68, P = 0.88). The HF Meta-score appeared to be accurate based on
the Brier score (value of 0.10) for predicting survival in patients with a
CRT-D as primary prevention of SCD.
In Table 3, baseline characteristics in ascending quintiles of the
HF Meta-score are presented. In the highest quintile, patients were
significantly older and sicker compared to the lowest quintiles, as
indicated by higher proportion of NYHA III–IV patients, more fre-
quent ischemic cardiomyopathy and higher prevalence of
comorbidity.dicted by the Heart Failure Meta-score.
Table 2
All-cause mortality by quintiles of HF Meta-score predicted risk.
Quintile HF Meta-score Total deaths HR (95% CI) P-value
I (n = 129) 0.64–1.75 12 (9%) Reference Reference
II (n = 130) 1.75–2.16 16 (12%) 1.4 (0.6–2.9) 0.41
III (n = 130) 2.16–2.59 26 (20%) 2.2 (1.1–4.4) 0.023
IV (n = 130) 2.59–3.05 38 (29%) 3.6 (1.9–6.9) <0.001
V (n = 129) 3.05–6.17 60 (47%) 6.9 (3.7–12.8) <0.001
Fig. 2. Calibration plot for the prediction of 5-year survival by the Heart Failure Meta-score.
distribution of patients is indicated with spikes at the bottom of the graph, stratified by endpo
Table 3





Age (y) 56 (50–62) 63 (55–
Male gender 90 (70%) 94 (72%
Atrial fibrillation 2 (2%) 17 (13%
Ischemic cardiomyopathy 25 (19%) 44 (34%
NYHA functional class
II 92 (71%) 58 (45%
III 37 (29%) 72 (55%
IV 0 (0%) 0 (0%)
LVEF (%) 27 ± 6 25 ± 6
QRS duration (ms) 169 ± 22 166 ±
Heart failure admission 1 year prior to implantation 6 (5%) 23 (25%
Comorbidities
Diabetes mellitus 7 (5%) 13 (10%
COPD 5 (4%) 8 (6%)
Peripheral vascular disease 3 (2%) 4 (3%)
Laboratory data
Sodium (mmol/l) 140 ± 3 140 ±
Hemoglobin (g/dl) 14.3 ± 1.5 13.9 ±
Creatinine (mg/dl) 0.9 (0.8–1.1) 1.0 (0.9
GFR (ml/min/1.73 m2) 81 (68–93) 71 (58–
GFR < 60 ml/min/1.73 m2 18 (14%) 37 (29%
Continuous data are expressed as mean ± SD or median (interquartile range), and categorical
COPD, chronic obstructive pulmonary disease; GFR, glomerular filtration rate; LVEF, left ventri
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At 5-years follow-up, 51 patients (8%) experienced an appropriate
ICD shock. The five-year cumulative incidence of appropriate ICD
shock was 4% in the lowest quintile and 12% in the highest quintile. A
total of 180 patients (28%) reached the secondary endpoint of time to
first appropriate ICD shock or death without prior appropriate ICD
shock. Of these patients, death without prior appropriate ICD shock
was observed in 129 patients (72%). In Fig. 3, the cumulative incidence
curves of death without prior appropriate ICD shock per quintile of theLegend: Triangles represent quintiles of patients grouped by similar predicted risk. The










68) 67 (61–71) 71 (65–75) 72 (67–77) <0.001
) 97 (75%) 108 (83%) 103 (80%) 0.08
) 19 (15%) 34 (26%) 53 (41%) <0.001
) 67 (52%) 79 (61%) 90 (70%) <0.001
) 31 (24%) 26 (20%) 12 (9%)
) 99 (76%) 101 (79%) 96 (74%) <0.001
0 (0%) 1 (1%) 21 (16%)
25 ± 6 24 ± 6 24 ± 6 <0.001
23 168 ± 21 163 ± 22 168 ± 27 0.37
) 39 (30%) 46 (35%) 84 (65%) <0.001
) 31 (24%) 51 (39%) 61 (47%) <0.001
10 (8%) 21 (16%) 41 (32%) <0.001
6 (5%) 12 (9%) 28 (22%) <0.001
3 139 ± 4 139 ± 5 138 ± 4 <0.001
1.6 13.7 ± 1.7 13.3 ± 1.9 13.0 ± 1.8 <0.001
–1.2) 1.2 (1.0–1.4) 1.3 (1.0–1.6) 1.6 (1.2–2.0) <0.001
89) 60 (48–78) 56 (44–68) 42 (32–60) <0.001
) 64 (49%) 79 (61%) 96 (74%) <0.001
data as number (percentage).
cular ejection fraction; NYHA, New York Heart Association.
Fig. 3. The 5-year cumulative incidence curves of mortality without prior appropriate ICD shock per risk quintile of the Heart Failure Meta-score.
D.A.M.J. Theuns, B.A. Schaer, K. Caliskan et al. International Journal of Cardiology xxx (xxxx) xxxHF Meta-score are presented. Death without prior appropriate ICD
shockwas almost 6 times higher for patients in the highest risk quintile
compared to the lowest risk quintile (SHR 5.8; 95% CI 3.1–11.0,
P < 0.001).
4. Discussion
In the present study, we evaluated the performance of the HF
Meta-score in patients with HFwho received CRT-D devices for primary
prevention of SCD. The main findings of our study are that (1) the cali-
bration of theHFMeta-score is excellent for prediction of survival in pa-
tients with a CRT-D, (2) the ability of the HFMeta-score to discriminate
between patients with low or high risk for mortality was good, and
(3) patients in the highest risk quintile were 5.8more likely to die with-
out ICD shock compared to patients in the lowest risk quintile.
Heart failure is a major cause of cardiovascular mortality and mor-
bidity, and its prevalence and incidence are still increasing [1]. In pa-
tients with HFrEF, NYHA class ≥ II, and prolonged QRS duration, CRT
improves clinical symptoms, reduces hospitalizations and prolongs
survival. The majority of patients eligible for CRT also qualify for defi-
brillator therapy as primary prevention of SCD. Based on this, current
guidelines advocate to implant a CRT-D in eligible patients [7,8]. Al-
though CRT-D therapy has been shown to decrease mortality and HF
events, the benefit of CRT-D is not uniform among patients. Accurately
predicting prognosis is important to identify those patients who will
likely not benefit from ICD back-up, and would be ipso facto candi-
dates for a CRT pacemaker. However, prediction of prognosis in pa-
tients with HFrEF is challenging due to the increasing proportion of
elderly patients who present with multiple comorbidities. To over-
come this problem, some investigators have developed predictive
models with the intent to identify patients who are at high risk for
all-cause mortality and who are therefore less likely to benefit from
defibrillator therapy. The SHFM was originally developed in the late
1990s when only a minority of patients received HF therapy according
to current practice [10]. Since its introduction, the SHFM underwent
several modifications [15] and has been validated in cohorts of pa-
tients treated with CRT-D. C-statistics ranged between 0.65 and 0.75
over a follow-up of 5 years [16–18].
Goldenberg et al. developed a score constructed of five risk factors to
assess benefit from ICD therapy based on theMADIT-II study population
consisting of patients with a previous myocardial infarction and
LVEF ≤ 30% [19]. In a post hoc analysis of MADIT-II cohort, patients
with 0–2 risk factors had a clear survival benefit from the ICD, whereas
patients with ≥3 risk factors had not [19]. Barra et al. evaluated the
MADIT-II score in patients treated with CRT [20]. They found similar5
results: benefit from a CRT-D decreased with increasing number of
risk factors. However, the prognostic performance of the MADIT II-
score is limited, C-statistics range between 0.61 and 0.71.
Previous studies have shown the substantial risk of mortality in pa-
tients with an ICD who have concomitant non-cardiac comorbidities
[21–24]. A recent meta-analysis of 4 major randomized clinical trials
evaluating the survival benefit of primary prevention ICDs demon-
strated that patients with extensive concomitant comorbidity may ex-
perience less benefit from ICD than those with less comorbidity [25].
In particular, diabetes, COPD, PVD, impaired renal function and AF are
independently associated with increased risk of mortality [24]. The im-
pact of comorbidities is commonly evaluated by using the Charlson co-
morbidity index [22–24]. Data from an Italian registry found that
patient age and a higher NYHA functional class in addition to comorbid-
ities are also important factors affecting patient outcome [23]. Prognosis
in HF is affected by a constellation of multiple factors. Using one factor
(e.g. age or NYHA class) or only a small number of factors (e.g. the
Charlson comorbidity index) will lead to suboptimal shared decision
makings. For example, an old patient may have better prognosis com-
pared to a NYHA class IV patient with impaired kidney function. The
use of scores incorporatingmultiple factorswith an impact on prognosis
most probably result in better patient selection or counseling.
In the current study, we evaluated the performance of the HFMeta-
score based on patient-level data including significant comorbidities,
age, LVEF and NYHA class, in order to predict prognosis [11]. The
performance of the HF Meta-score was good in predicting short- and
long-term survival, with C-statistics ranging between 0.76 at 1-year
follow-up and 0.71 at 5-years follow-up. The HFMeta-score showed ex-
cellent calibration and accuracy.We found that increasingmortality risk
at the time of CRT implant was associatedwith less benefit from the ICD
as defined by the occurrence of death without receiving an appropriate
ICD shock. When looking at clinical variables, patients at high risk for
mortality were older, had more ischemic cardiomyopathy, and a high
number of comorbidities. These results pose uncertainty regarding the
utilization of a CRT-D in high risk patients in whom a CRT pacemaker
(CRT-P) may be a more appropriate approach.
In the landmark COMPANION trial, the difference in all-cause mor-
tality between CRT-D and CRT-P was not tested [4]. A few studies
have attempted to compare the outcomes between CRT-P and CRT-D
patients [26,27]. A large multicenter prospective registry, CeRtiTuDe,
evaluated the characteristics of CRT-P versus CRT-D patients in a real-
world scenario [28]. Cause-of-death analysis demonstrated that excess
mortality among CRT-P patients was almost entirely related to non-
SCD. The CRT-P patients were older, had more advanced heart failure
and co-morbidities when compared to CRT-D patients. This finding
D.A.M.J. Theuns, B.A. Schaer, K. Caliskan et al. International Journal of Cardiology xxx (xxxx) xxxwas also confirmed in a meta-analysis to determine the importance of
ICD back-up in CRT recipients [29]. Patients with ischemic cardiomyop-
athy seemed to benefit from the addition of the ICD, while such benefit
was less clear in those with non-ischemic cardiomyopathy. Another rel-
evant finding was that patients with non-ischemic cardiomyopathy re-
ceiving CRT-P were in general older, had more advanced heart failure
and a higher number of comorbidities compared to non-ischemic CRT-
D patients. Taking everything together, the use of the HF Meta-score
may assist physicians in the shared decision-making process with HF
patients eligible for CRT-D as primary prevention of SCD. In a subgroup
of these patients, competing risks of non-sudden death may diminish
the value of ICD back-up to CRT.
4.1. Limitations
The present study had some limitations. First, this observational
study is limited by the non-randomized design. However, the results
of this study are representative for patientswho received a CRT-D as pri-
mary prevention in routine clinical practice. Future changes in therapy
and management strategies might improve patient outcomes and po-
tentially change the association between predictors and outcomes. In
general, the performance of risk models should be retested routinely
in order to determine whether discrimination is still adequate. The
study cohort included patients over a 12-year period, during which
treatment of HF changed. In the same period, the programming of de-
vices with respect to detection and treatment of ventricular arrhyth-
mias changed. We accounted for this by defining three groups
according to the date of implant, where no difference was noticed.
A recent model the Seattle Proportional Risk Models (SPRM) has
beendeveloped to estimate the proportion of totalmortality due to sud-
den death in order to determine ICD benefit [30]. The HFMeta-score has
been developed to predict the risk of all-cause mortality and not specif-
ically causes of death as in the SPRM. Comparison of the HF Meta-score
with the SPRM is beyond the scope of the current study.
4.2. Conclusion
The present study found that the HFMeta-score has a very good per-
formance to predict survival in HF patients treated at the time of CRT-D
implantation as primary prevention of SCD. The HF Meta-score proved
to be useful in identifying a subgroup of patients with poor prognosis
and high probability of death prior to receiving ICD shock therapy, fa-
voring the sole implant of CRT. The use of the HFMeta-score may assist
physicians in a more personalized shared decision-making process of
HF patients with different prognosis who are potentially eligible for
CRT-D as primary prevention of SCD.
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